UNC-Chapel Hill Receives $65M from NIH for Antiviral Drug Development Center

Consortium Formed to Discover Antivirals for COVID-19 Receives NIH Funding to Develop Globally Accessible Treatments for Pandemics

Link Type
Funded-research
Publish or Event Date
Link URL
https://dndi.org/press-releases/2022/consortium-to-discover-antivirals-covid19-receives-nih-funding-develop-globally-accessible-treatments-pandemics/
Research Institution
DNDi
Short Title
Consortium Formed to Discover Antivirals for COVID-19 Receives NIH Funding to Develop Globally Accessible Treatments for Pandemics
Content Coordinator
Claudia Wair

UCSF Awarded $67.5 Million to Develop New Antiviral Therapies

Scripps Research Awarded $67 Million by NIH to Lead New Pandemic Preparedness Center

Revolutionary Mosquito Researchers Receive $2.7 Million Grant

Mapping Dengue Hot Spots Pinpoints Risks for Zika and Chikungunya

NIAID Announces Antiviral Drug Development Awards

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Self-eliminating genes tested on mosquitoes

NIAID Pandemic Preparedness Plan Targets ‘Prototype’ and Priority Pathogens

The National Institute of Allergy and Infectious Diseases is focusing on preparing for a range of other viral threats that could cause a public health emergency, and according to NIAID’s new Pandemic Preparedness Plan, the institute will direct its preparedness efforts on two fronts.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Scientists Find Antibody that Blocks Dengue Virus

Subscribe to Flaviviruses